We provide you with 20 years of free, institutional-grade data for YMAB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of YMAB. Explore the full financial landscape of YMAB stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| GILL DAVID N | Grant, award...etc | 25,080 | 2025-07-02 | ||
| Hamill Laura | Grant, award...etc | 25,080 | 2025-07-02 | ||
| TYAGI ASHU | Grant, award...etc | 25,080 | 2025-07-02 | ||
| HEALY JAMES | Grant, award...etc | 25,080 | 2025-07-02 | ||
| Wedell-Wedellsborg Johan | Grant, award...etc | 25,080 | 2025-07-02 | ||
| Gad Thomas | Derivatives Exercise | 103,000 | 2025-06-05 | ||
| Rossi Michael J | Sale | -3,917 | $5.2 | $20,368 | 2025-03-11 |
| Gad Thomas | Sale | -10,810 | $5.23 | $56,536 | 2025-03-11 |
| Rossi Michael J | Grant, award...etc | 105,300 | 2025-01-22 | ||
| LaRocca John | Grant, award...etc | 21,500 | 2025-01-22 | ||
| Wilms Joris | Grant, award...etc | 21,500 | 2025-01-22 | ||
| Gad Thomas | Grant, award...etc | 32,000 | 2025-01-22 | ||
| PFREUNDSCHUH PETER P. | Grant, award...etc | 31,800 | 2025-01-22 | ||
| Gad Thomas | Derivatives Exercise | 22,831 | 2024-09-20 | ||
| Gad Thomas | Sale | -95,000 | $13.47 | $1,279,650 | 2024-09-17 |
| Lund-Hansen Torben | Sale | -50,000 | $15.37 | $768,500 | 2024-08-30 |
| Lund-Hansen Torben | Derivatives Exercise | 50,000 | 2024-08-30 | ||
| Wilms Joris | Sale | -5,000 | $14.69 | $73,450 | 2024-08-27 |
| PFREUNDSCHUH PETER P. | Grant, award...etc | 46,000 | 2024-07-12 | ||
| TYAGI ASHU | Grant, award...etc | 3,495 | 2024-06-13 | ||
| GILL DAVID N | Grant, award...etc | 3,495 | 2024-06-13 | ||
| Wedell-Wedellsborg Johan | Grant, award...etc | 3,495 | 2024-06-13 | ||
| TAGLIAFERRI MARY | Grant, award...etc | 3,495 | 2024-06-13 | ||
| Hamill Laura | Grant, award...etc | 3,495 | 2024-06-13 | ||
| HEALY JAMES | Grant, award...etc | 3,495 | 2024-06-13 | ||
| Ber Gerard | Sale | -722 | $12 | $8,664 | 2024-06-11 |
| Gad Thomas | Sale | -70,000 | $12.03 | $842,100 | 2024-06-11 |
| Kruse Bo | Sale | -60,000 | $12.03 | $721,800 | 2024-05-31 |
| Kruse Bo | Derivatives Exercise | 60,000 | 2024-05-31 | ||
| Gad Thomas | Sale | -32,351 | $12 | $388,212 | 2024-05-23 |
| TAGLIAFERRI MARY | Grant, award...etc | 4,660 | 2024-03-14 | ||
| Gad Thomas | Sale | -3,900 | $16.44 | $64,116 | 2024-03-07 |
| Smith Susan Laura | Sale | -1,682 | $16.55 | $27,837 | 2024-03-07 |
| Rajah Vignesh | Sale | -1,711 | $16.53 | $28,283 | 2024-03-07 |
| Rossi Michael J | Grant, award...etc | 35,700 | 2024-02-14 | ||
| Lisby Steen | Grant, award...etc | 17,800 | 2024-01-22 | ||
| Gad Thomas | Grant, award...etc | 22,100 | 2024-01-22 | ||
| Lund-Hansen Torben | Grant, award...etc | 17,800 | 2024-01-22 | ||
| Wilms Joris | Grant, award...etc | 17,800 | 2024-01-22 | ||
| Kruse Bo | Grant, award...etc | 18,100 | 2024-01-22 | ||
| Rajah Vignesh | Grant, award...etc | 17,800 | 2024-01-22 | ||
| Smith Susan Laura | Grant, award...etc | 17,800 | 2024-01-22 | ||
| Gad Thomas | Derivatives Exercise | 50,000 | 2023-12-26 | ||
| Gad Thomas | Sale | -150,000 | $6.58 | $987,000 | 2023-12-15 |
| Wedell-Wedellsborg Johan | Open Market Purchase | 6,455 | $6.85 | 2023-12-12 | |
| WG Biotech ApS | Open Market Purchase | 6,455 | $6.85 | 2023-12-12 | |
| WG Biotech ApS | Open Market Purchase | 127,549 | $6.5 | 2023-12-11 | |
| Wedell-Wedellsborg Johan | Open Market Purchase | 127,549 | $6.5 | 2023-12-11 | |
| WG Biotech ApS | Open Market Purchase | 51,837 | $5.97 | 2023-12-01 | |
| Wedell-Wedellsborg Johan | Open Market Purchase | 51,837 | $5.97 | 2023-12-01 | |
| Wedell-Wedellsborg Johan | Open Market Purchase | 93,187 | $5.49 | 2023-11-29 | |
| WG Biotech ApS | Open Market Purchase | 93,187 | $5.49 | 2023-11-29 | |
| Gad Thomas | Sale | -150,000 | $5.3 | $794,790 | 2023-11-22 |
| Ber Gerard | Grant, award...etc | 2,330 | 2023-06-09 | ||
| HEALY JAMES | Grant, award...etc | 2,330 | 2023-06-09 | ||
| GILL DAVID N | Grant, award...etc | 2,330 | 2023-06-09 | ||
| TYAGI ASHU | Grant, award...etc | 2,330 | 2023-06-09 | ||
| Hamill Laura | Grant, award...etc | 2,330 | 2023-06-09 | ||
| Wedell-Wedellsborg Johan | Grant, award...etc | 2,330 | 2023-06-09 | ||
| Wedell-Wedellsborg Johan | Open Market Purchase | 101,740 | $9.65 | 2023-05-17 | |
| WG Biotech ApS | Open Market Purchase | 101,740 | $9.65 | 2023-05-17 |
The information provided in this report about YMAB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Y-mAbs Therapeutics, Inc(NASDAQ:YMAB) 
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophag...
Website: http://www.ymabs.com
Founded: 2015
Full Time Employees: 65
Sector: Healthcare
Industry: Biotechnology